Alzheimer's Treatment Pharmas on Watch as Merz Gets Positive CHMP Opinion for Memantine MAA
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan (Nasdaq: MYL), Elan (NYSE: ELN), Forest Labs (NYSE: FRX), and others are on watch Friday morning following Germany's Merz getting a positive opinion from the EMA CHMP on its marketing app for Memantine.
Memantine is indicated for the treatment of moderate-to-severe Alzheimer's disease.
Forest currently has NAMENDA while a Mylan unit recently got FDA approval for generic Aricept. Elan, Pfizer (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ) were in collaboration for proposed Alzheimer's treatment bapineuzumab, but the drug failed to meet co-primary endpoints in Phase 3 over the summer.
Memantine is indicated for the treatment of moderate-to-severe Alzheimer's disease.
Forest currently has NAMENDA while a Mylan unit recently got FDA approval for generic Aricept. Elan, Pfizer (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ) were in collaboration for proposed Alzheimer's treatment bapineuzumab, but the drug failed to meet co-primary endpoints in Phase 3 over the summer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA grants Nuvation Bio fast track status for brain cancer drug
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
